Blood cancers get new enemy
In one of the biggest advances against leukemia and other blood cancers in many years, doctors are reporting unprecedented success by using gene therapy to transform patients' blood cells into soldiers that seek and destroy cancer.
A few patients with one type of leukemia were given this one-time, experimental therapy several years ago, and some remain cancer-free. Now at least six research groups have treated more than 120 patients with many types of blood and bone marrow cancers, drawing stunning results.
“It's really exciting,” said Dr. Janis Abkowitz, blood diseases chief at the University of Washington in Seattle and president of the American Society of Hematology. “You can take a cell that belongs to a patient and engineer it to be an attack cell.”
In one study, all five adults and 19 of 22 children with acute lymphocytic leukemia, or ALL, had a complete remission, meaning no cancer could be found after treatment, although a few have relapsed since then.
These were gravely ill patients out of options. Some had tried multiple bone marrow transplants and up to 10 types of chemotherapy or other treatments.
Cancer was so advanced in 8-year-old Emily Whitehead of Philipsburg, Pa., that doctors said her major organs would fail within days. She was the first child given the gene therapy and shows no sign of cancer nearly two years later.
Results on other patients with myeloma, lymphoma and chronic lymphocytic leukemia, or CLL, will be reported at the hematology group's conference, which started Saturday in New Orleans.
Doctors say this has the potential to become the first gene therapy approved in the United States and the first for cancer worldwide. Only one gene therapy is approved in Europe, for a rare metabolic disease.
The treatment involves filtering patients' blood to remove millions of white blood cells called T-cells, altering them in the lab to contain a gene that targets cancer, and returning them to the patient in infusions over three days.
“What we are giving essentially is a living drug” — permanently altered cells that multiply in the body into an army to fight the cancer, said Dr. David Porter, a University of Pennsylvania scientist who led one study.
Several drug and biotech companies are developing these therapies. Penn has patented its method and licensed it to Switzerland-based Novartis AG. The company is building a research center on the Penn campus in Philadelphia and plans a clinical trial next year that could lead to federal approval of the treatment as soon as 2016.
Talking with the researchers, “there is a sense of making history ... a sense of doing something very unique,” said Hervé Hoppenot, president of Novartis Oncology, the division leading the work.
Lee Greenberger, chief scientific officer of the Leukemia and Lymphoma Society, agreed.
“From our vantage point, this looks like a major advance,” he said. “We are seeing powerful responses ... and time will tell how enduring these remissions turn out to be.”
The group has given $15 million to various researchers testing this approach.
Many patients are successfully treated with chemotherapy or bone marrow or stem cell transplants, but transplants are risky, and donors can't always be found. So far, gene therapy has been tried on people who were in danger of dying because other treatments failed.
The gene therapy must be made individually for each patient, and lab costs are about $25,000 without a profit margin. That is still less than many drugs to treat these diseases and far less than a transplant.
Show commenting policy
TribLive commenting policy
- Snow causes roof to collapse at Crawford County plastics plant
- Wolf to outline charter school plan in budget address
- 1 killed in Lawrence County tractor-trailer crash
- As House looks to dismantle state stores, hybrid system might be option
- ‘Tipping point’ near for Pa. government, conservative expert predicts at Freedom Forum
- Husband charged in ax murder of wife hangs himself in cell
- 242 Pennsylvania workers not state residents